Belgian drugmaker UCB is navigating a familiar tension in the pharmaceutical industry: expanding patient access to a blockbuster drug while managing the financial hit from larger rebates. That balancing act was at the center of a fresh analyst note from Germany's Berenberg, which raised its 2026 revenue and earnings-per-share forecasts for UCB even as it acknowledged that pricing pressure on the company's key product, Bimzelx, is set to intensify in the second half of the year.
Berenberg's updated outlook follows UCB's first-half results, which the bank said beat expectations. The note, published Tuesday, argues that prescription volume growth for Bimzelx—a treatment for inflammatory conditions such as psoriasis and psoriatic arthritis—should outrun the drag from higher rebates. In other words, more patients taking the drug should more than compensate for the lower net price per prescription.
Why pricing pressure is building
Bimzelx has been a growth engine for UCB, but its path to wider use comes with costs. To secure favorable formulary placement and insurance coverage, drugmakers often offer rebates to pharmacy benefit managers and insurers. Those rebates reduce the net revenue the company actually pockets, even when gross sales rise. Berenberg expects these rebates to weigh more heavily on Bimzelx's pricing in the second half, a pattern that is common as a drug's market presence expands and competition intensifies.
The bank's decision to lift its 2026 forecasts suggests it believes the volume story is strong enough to overcome that headwind. For investors, the key takeaway is that UCB's top-line growth may look healthy, but the quality of that growth—measured by how much of it flows to the bottom line—will depend on how effectively the company manages rebate dynamics.
Market reaction and guidance
Despite the upbeat first-half performance, UCB's stock reaction was muted. Management guided Bimzelx peak sales to “at least” €7 billion, a figure that landed below the roughly €8 billion some analysts had been expecting. That gap helps explain why the shares didn't rally more decisively. Investors often focus on peak sales estimates as a proxy for a drug's long-term potential, so a lower-than-expected ceiling can temper enthusiasm even when near-term results are solid.
Berenberg's revised forecasts, however, suggest the bank sees room for upside beyond the company's own guidance. By raising its 2026 revenue and EPS numbers, Berenberg is signaling that it expects Bimzelx's volume trajectory to deliver more than the market currently prices in.
What it means for everyday investors
For ordinary investors, this story illustrates a core dynamic in pharmaceutical investing: the difference between gross sales and net revenue. A drug can generate headlines with strong prescription numbers, but the actual money a company keeps depends on rebates, discounts, and payer negotiations. When a drug's volume grows rapidly, it can mask pricing erosion—but that erosion eventually shows up in margins.
UCB's situation also highlights how analyst forecasts and company guidance can diverge. When a company sets a conservative peak-sales target, it can create a ceiling on investor expectations. But if analysts like Berenberg see reasons to be more optimistic, that can open the door for upward revisions—and potentially a re-rating of the stock if those forecasts prove accurate.
Investors holding UCB shares, or considering a position, should watch how Bimzelx's net pricing evolves in the coming quarters. If rebates rise faster than volume, the company's earnings growth could disappoint. Conversely, if volume growth continues to outpace pricing pressure, UCB could beat the higher forecasts that Berenberg and others have set.
The broader lesson applies beyond UCB: in the pharma sector, the path from prescription to profit is rarely straight. Rebates, access deals, and competitive dynamics all shape the final numbers. For that reason, analysts' estimates—and the assumptions behind them—are often as important as the headline sales figures.
Berenberg's move is a vote of confidence in UCB's ability to manage that complexity. Whether the market ultimately agrees will depend on the data UCB delivers in the second half and beyond.
